Poging GOUD - Vrij
“Our ambition requires us to take long-term view, investing in scale and building unmatched capabilities”
BioSpectrum Asia
|January 2023
The novel trend in single-cell analysis is revolutionising biological research, unravelling underlying genetic credentials while creating new therapeutic approaches and personalised treatments.
 For it to become more feasible, powerful, reliable tools can fuel scientific discoveries and drive exponential progress to refine genetic analysis for developing better treatment regimens. A study by Grand View Research reveals that the global single-cell analysis market size was valued at 3.28 billion in 2021 and is expected to expand at a compound annual growth rate CAGR) of 18.5 per cent from 2022 to 2030. Aware of the burgoing growth of single-cell-analysis market, Dr Ben Hindson, President Co-Founder of 10x Genomics explains how innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more areas using innovative diagnosis and therapy techniques.
What are the drivers and trends shaping the single-cell-analysis market? How do you Identify growth segments for investment and expansion?
More and more, we see that single cell methods are becoming the standard for a growing fraction of life science research, an essential element of many new grant applications and are increasingly becoming a requirement for publication.
Our goal at 10x Genomics is to make single cell analysis accessible to every biology lab in the world to make it the standard for most biological research.
Since the initial launch of our Single Cell Gene Expression solution, we have released many new capabilities and versions of our products focused on expanding the range of applications on the platform, including immune-profiling, epigenetics, proteins and multi-omics.
We have expanded the fundamental capabilities of the platform, highlighted by the release of the Chromium X instrument, which has made it possible for people to run up to 1 million cell experiments routinely.
Dit verhaal komt uit de January 2023-editie van BioSpectrum Asia.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN BioSpectrum Asia
 BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
 BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size
